Please try another search
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Name | Age | Since | Title |
---|---|---|---|
Charles L. Pope | 72 | 2010 | Executive Chairman |
Frederick W. Telling | 72 | 2010 | Independent Director |
Robert Clayton Koski | 65 | 2009 | Independent Director |
Kimberly M. Murphy | 60 | 2020 | Director |
Timothy Cooke | - | - | Member of Scientific Advisor |
Alan W. Dunton | 70 | 2011 | Independent Director |
David Zarley | - | - | Member of Scientific Advisor |
Terrence Cochrane | - | - | Member of Scientific Advisor |
John P. Gandolfo | 63 | 2023 | Independent Director |
Bruce A. Cassidy | 73 | 2023 | Independent Director |
James P. Kelly | - | 2024 | Chief Medical Officer & Member of Scientific Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review